ERBB2 and breast carcinoma: Despite the lack of statistical power in our analysis to rule out small benefits for one regimen versus the other, the similar 10-year iDFS, BCSS and OS rates for the matched DC4 and AT groups are reassuring and provide evidence to support the ongoing use of adjuvant DC4 for HER2-negative, LNN breast cancer.